Ceftriaxone, a new third-generation cephalosporin, appears to be promising for the therapy of acute bacterial meningitis. The 90% MBCs of ceftriaxone against 54 recent cerebrospinal fluid isolates of Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae were .0.06 to 0.25 j.Lg/ml. We examined the efficacy and safety of ceftriaxone therapy of meningitis in Bahia, Brazil. The study was conducted in two phases; in phase A, ceftriaxone was coadministered with ampicillin. The mean cerebrospinal fluid concentrations of ceftriaxone 24 h after an intravenous dose of 80 mg/kg were 4.2 and 2.3 ,ug/ml on days 4 to 6 and 10 to 12 of therapy, respectively. These concentrations were 8-to more than 100-fold greater than the 90% MBCs against the relevant pathogens. In phase B, ceftriaxone (administered once daily at a dose of 80 mg/kg after an initial dose of 100 mg/kg) was compared with conventional dosages of ampicillin and chloramphenicol in a prospective randomized trial of 36 children and adults with meningitis. The groups were comparable based on clinical, laboratory, and etiological parameters. Ceftriaxone given once daily produced results equivalent to those obtained with ampicillin plus chloramphenicol, as judged by cure rate, case fatality ratio, resolution with sequelae, type and severity of sequelae, time to sterility of cerebrospinal fluid, and potentially drug-related adverse effects. The cerebrospinal fluid bactericidal titers obtained 16 to 24 h after ceftriaxone dosing were usually 1:512 to >1:2,048 even late in the treatment course, compared with values of 1:8 to 1:32 in patients receiving ampicillin plus chloramphenicol. Ceftriaxone clearly deserves further evaluation for the therapy of meningitis; the optimal dose, dosing frequency (every 12 h or every 24 h), and duration of therapy remain to be determined.
Bacterial meningitis remains a relatively common disease worldwide. The recent emergence of pneumococci resistant to penicillin or chloramphenicol or both (18, 27) , the emergence of Haemophilus influenzae strains resistant to ampicillin or chloramphenicol or both (16, 32, 44, 45) , the continued high mortality due to gram-negative bacillary meningitis despite therapy with aminoglycosides or chloramphenicol or both (7) , and the potential toxicity of chloramphenicol have all prompted the search for alternative agents for the therapy of meningitis.
Ceftriaxone (RO13-9904) is a new third-generation cephalosporin with excellent in vitro activity against all major meningeal pathogens (1, 14, 17, 28, 39 ; Scheld, Rocha, Sande, and Bryan, Am. J. Med., in press), except Listeria monocytogenes. In addition, ceftriaxone was the most rapidly bactericidal agent within the cerebrospinal fluid (CSF) in vivo when it was compared with moxalactam, cefotaxime, ampicillin, and netilmicin in experimental animal models of meningitis induced by Escherichia coli, Streptococcus agalactiae, Streptococcus pneumoniae, or H. influenzae (9, 11, 24, 34; Scheld et al., in press). Although the ceftriaxone concentrations in CSF are only a small fraction (-3 to 9%) of the concurrent serum concentrations, the bactericidal activity of this agent in CSF routinely exceeds the 90% MBC (MBC90) for the most common meningeal pathogens (5, 13, 20, 21, 26, 35; Scheld et al., in press).
Encouraging results have been obtained by using ceftriaxone for therapy of meningitis in open clinical trials (3, 4) .
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of the Federal University of Bahia in Salvador or at the University of Virginia in Charlottesville. Patients with historical, clinical, and laboratory findings consistent with acute bacterial meningitis were admitted to the study. Patients who were less than 2 months old or pregnant or who had a history of allergy to ,B-lactam antibiotics or recurrent meningitis were excluded from entrance. In phase B we evaluated patients who (i) survived .6 h after hospitalization, (ii) had CSF culture or Gram stain proof of bacterial meningitis, or (iii) had .10,000 leukocytes per mm3 of CSF (predominantly polymorphonuclear leukocytes), a protein concentration of .250 mg/dl, and a glucose concentration .20 mg/dl. Patients who had a history of prior antibiotic usage and whose cultures were negative were excluded.
Drug administration. This study was conducted in two phases and was similar to a previous study conducted in Brazil (15) . Phase A was designed to evaluate the pharmacokinetics of ceftriaxone and to determine the CSF concentration achieved 24 h after a dose of 80 mg/kg at two time points during the disease course. Phase B was a comparative randomized trial. Patients in phase A received ampicillin (300 mg/kg per day intravenously in six divided doses) plus ceftriaxone given as a loading dose of 75 mg/kg followed by 50 mg/kg every 12 h. However, on days 4 to 6 and again on days 10 to 12 of therapy, a single 80-mg/kg dose of ceftriaxone was given, followed by collection of CSF and serum 24 h later. Ampicillin treatment was continued at the above dose throughout therapy, and ceftriaxone was given at a dose of 50 mg/kg every 12 h except on the 2 days when the 80-mg/kg dose was administered. After inactivation of the ampicillin by the addition of 10% penicillinase (Difco Laboratories, Detroit, Mich.), the CSF ceftriaxone concentrations were determined by the bioassay method described below. Since these ceftriaxone concentrations achieved in CSF 24 h after dosing far exceeded the MBC90 values of the major meningeal pathogens, a prospective randomized trial was initiated.
Phase B was an open prospective randomized trial in which we compared a group receiving ceftriaxone (administered as a loading dose of 100 mg/kg, followed by 80-mg/kg doses every 24 h) with a group receiving ampicillin (given as a 75-mg/kg loading dose, followed by 50 mg/kg every 4 h) plus chloramphenicol (given as a 50-mg/kg loading dose, followed by 25 mg/kg every 6 h). All doses were intravenous. All patients except those with meningococcal disease were treated for at least 10 days; patients with meningococcal disease were given 7 days of therapy. Patients were enrolled and assigned randomly (by a random number therapy (24 h after dosing) was 4.2 + 1.9 ,ug/ml (range, 1 to 5.4 ,ug/ml; n = 7). In contrast, on days 10 to 12 of therapy the mean concentration was 2.3 + 0.9 ,ug/ml (range, 1.0 to 3.7 ,ug/ml; n = 7). A ventricular fluid level of 12.5 jig/ml 24 h after the dose was noted on day 4 of treatment in one patient. Because these concentrations all exceeded (>10-fold) the MBCs for the three most common bacterial pathogens 24 h after dosing, we proceeded with phase B, the comparative trial.
A total of 52 patients were originally enrolled in phase B, the controlled comparative trial in which we evaluated ceftriaxone alone (given every 24 h) and ampicillin plus chloramphenicol: 16 patients were excluded, as shown in Table 1 . There were 18 patients in each group. The pretreatment characteristics of the patients in each group are shown in Table 2 . The groups were very comparable on the basis of clinical and laboratory criteria. The mean duration of meningeal symptoms was -4 days in both groups, reflecting the delays in hospitalization often encountered in this area of Brazil. We feel that the statistical difference in the frequency of positive blood cultures between the groups has little significance. Blood cultures are not routinely drawn from patients with meningitis at Hospital Couta Maia. Several cultures were contaminated, whereas others may have been drawn after antibiotic treatment was initiated. The etiological agents are shown in Table 3 . It should be noted that the ceftriaxone group included two patients with meningitis due to members of the Enterobacteriaceae (one of which had failed 48 h of therapy with ampicillin plus chloramphenicol). None of the H. influenzae isolates produced beta-lactamase.
Response to therapy. Patients could be evaluated if survival exceeded 6 h after admission. There were three deaths in the control group and four in the ceftriaxone group. In the control group, a 14-year-old girl with pneumococcal meningitis was admitted comatose after 2 days of high fever. She developed respiratory arrest 6 h later and required assisted ventilation. She died after 7 (Tables 4 and 5 ). The CSF bactericidal titers in the ceftriaxone group were generally higher than those predicted from the ratio of the CSF ceftriaxone concentration to the MBC for the infecting strain. Similar dichotomous values have been noted in humans receiving ceftriaxone for meningitis (12) , but the explanation for this phenomenon is unclear. The MBC9os of ceftriaxone for recent CSF isolates, including H. influenzae (n = 33), S. pneumoniae (n = 9), Neisseria meningitidis (n = 7), and Salmonella group B (n = 5), were <0.06 to 0.25 ,uig/ml.
The ceftriaxone concentrations achieved in the CSF and serum after a loading d )f 100 mg/kg were high. The CSF concentrations attained ,.,er 2 h were 19.7 ± 10.6 ,ug/ml (mean ± standard deviation), and these concentrations were maintained for 24 h. The CSF concentrations were 10.5 ± 5.5 ,ug/ml 24 h after the initial loading dose (at least 90-fold higher than the MBC9o of ceftriaxone against the three major meningeal pathogens). The serum and CSF concentrations of ceftriaxone achieved at different times after intravenous doses of 80 mg/kg on days 2 to 4 and 8 to 12 of therapy are shown in Fig. 1 and 2 , respectively. The CSF concentrations of ceftriaxone achieved with 80-mg/kg doses were less but very adequate (mean, 1.4 ,ug/ml 20 to 24 h after the dose on days 2 to 4 of treatment). The concentrations in CSF on days 8 to 12 of therapy remained >1.0 ,ug/ml (mean, 1.5 ,ug/ml 20 to 24 h after dosing) ( Fig. 1 and 2 ). These concentrations were substantiated by the excellent CSF bactericidal titers attained (Table 4 ). Ventricular fluid concentrations of 100 and 18.9 ,ug/ml were attained in two patients 12 We found no statistically significant differences in clinical, laboratory, or etiological characteristics between the two groups analyzed in phase B, the prospective randomized trial. The results of therapy were essentially identical in the two groups, as judged by cure rate, case fatality ratios, neurological sequelae, and possible drug-related toxicity. However, the CSF bactericidal titers achieved 16 to 24 h after intravenous infusion of 80 mg of ceftriaxone per kg (1:64 to -1:2,048) were substantially higher than values obtained (generally 1:8 to 1:32) at varying intervals after dosing with ampicillin plus chloramphenicol in the control group (Tables 4 and 5 ). Much higher bactericidal titers might be expected during ceftriaxone therapy if specimens were obtained in the first several hours after dosing on day 1 of treatment. Nevertheless, the rates of bacterial killing within purulent CSF, as judged by the percentage of CSF samples rendered sterile within 48 h of initiation of therapy, were similar (83 to 85%) in the two groups. Similar high bactericidal titers in CSF during ceftriaxone therapy and equivalent rates of bacterial killing (compared with ampicillin plus chloramphenicol) have been noted by other workers (8, 12, 40 ) (see below). The mortality rate in this study was high and does not include two patients who died of fulminant meningitis within 3 h of admission. The overall case fatality rates were 17 and 22% for patients treated with ampicillin plus chloramphenicol and patients treated with ceftriaxone, respectively. This high level of mortality reflects the poor general condition of these patients on admission with advanced disease and the local results in Bahia, Brazil. In a retrospective analysis of the outcome of 4,101 cases of bacterial meningitis at Hospital Couta Maia from 1973 to The results of the present study are in general agreement with those reported by other workers (3, 4, 8, 12, 23, 40) who evaluated ceftriaxone for therapy of bacterial meningitis. Cadoz and colleagues were the first to describe (3, 4) the use of ceftriaxone for therapy of meningitis. These authors compared this agent with amoxicillin alone, but their analysis was retrospective and the patients were treated at dif- ferent periods in time. A large number of patients were treated (more than 300), and the mortality rate was high (4), similar to results obtained in other locales in the developing world and higher than our experience in Brazil. Nevertheless, the results achieved with ceftriaxone, which was generally administered twice daily, were equivalent (or better in cases of pneumococcal meningitis) to those obtained with amoxicillin (4) . Importantly, some patients with meningococcal meningitis were cured by a single administration of ceftriaxone, and the mean duration of therapy was only 3 days in this group of patients (4) .
Three other groups of workers have recently evaluated the comparative efficacy of ceftriaxone for the therapy of bacterial meningitis (8, 12, 40) . All of these studies were performed in the United States, and they included a total of 153 cases. Unlike the present study, only pediatric age groups were enrolled, and very few patients were more than 2 years old. Each trial was randomized and prospective and compared ceftriaxone (50 mg/kg given twice daily intravenously or intramuscularly) with standard parenteral doses of ampicillin plus chloramphenicol. Thus, in four studies workers have compared ceftriaxone with standard, accepted regimens for the therapy of meningitis, an unusual occurrence since only two other prospective randomized trials evaluating a new agent for treatment of meningitis have been performed in the last 17 years (43; S. L. Kaplan, E. 0. Mason, S. J. Kvernland, et al., Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 22nd, abstr. no. 314, 1982) . Ceftriaxone has been scrutinized carefully for this indication. In the other three studies (8, 12, 40) the authors described the results of twice daily dosing, and no CSF concentrations 24 h after dosing were determined, unlike the present study. Nevertheless, in all four trials ceftriaxone proved to be equivalent to (or slightly better than) ampicillin plus chloramphenicol, as judged by the following parameters: outcome (cure, death, resolution with sequelae); number of days of fever or signs of meningitis; type and severity of sequelae; resolution of abnormal CSF findings; time to sterility of CSF; differences in CSF bactericidal titers; tolerance; and adverse effects potentially related to the study drugs. However, the equivalent results must be interpreted with caution due to the rather small number of patients enrolled (less than <40) (8, 40) , including the small number of patients in this study (n = 36), and the large potential ,-error in this situation. The evidence certainly suggests that ceftriaxone given once or twice daily produces results similar to those obtained in patients receiving ampicillin plus chloramphenicol. Remarkably, only 3 of 153 patients died, and there were no deaths in two of the trials (12, 40) ; however, exclusions due to early deaths after admission are not mentioned. In two of the studies, the time to achieve sterility and negative Gram stains of CSF was shorter, but did not differ significantly, in the ceftriaxone group (12, 40) . In the present study, 15% of the CSF samples were still positive 22 to 48 h after the initiation of therapy in both study groups. In addition, the CSF remained culture positive in one patient with group B Salmonella meningitis despite 6 days of ceftriaxone therapy and CSF bactericidal titers of 1:32 to 1:256. Such a prolonged period of positive CSF cultures has been noted in cases of Salmonella meningitis treated with other regimens (31, 43, 46) and remains unexplained, although an intracellular location or protected sanctuaries of the organisms may be responsible.
The CSF bactericidal titers reported in the four prospective randomized trials, including the present study, are remarkably similar (8, 12) . Against the most common meningeal pathogens, the CSF bactericidal titers were generally 1:8 to 1:32 and 1:512 to >1:2,048 for ampicillin plus chloramphenicol and ceftriaxone, respectively. Despite the much higher bactericidal titers in CSF, the rate of bacterial killing in vivo, the time to sterility of CSF, and the outcome were not significantly improved during ceftriaxone therapy compared with therapy with ampicillin plus chloramphenicol. Experimental evidence (10, 37) and clinical evidence (6, 7, 23) strongly support the need for bactericidal activity in CSF for optimal therapy of meningitis. CSF antibiotic concentrations exceeding the MBC of the pathogen by -10-fold have been suggested for maximal rates of bacterial killing within purulent CSF in vivo (33, 37) . The results of other studies (8, 12, 40) and our results support this concept since outcome and rate of response within CSF were equivalent, with median CSF bactericidal titers of 1:8 (ampicillin plus chloramphenicol) and 1:1,024 (ceftriaxone). Thus, increasing the CSF bactericidal titer manyfold in excess of 1:8 may not be reflected in improved response rates or eventual outcome.
As described above, ceftriaxone may prove to be useful in the therapy of bacterial meningitis. This agent displays many desirable characteristics for this indication compared with other cephalosporins. The accumulated experience with first-and second-generation cephalosporins for the therapy of meningitis has provided unimpressive results, with many failures (10, 19) . Cefuroxime, a new second-generation agent, may prove to be an exception. Cefuroxime was equivalent to ampicillin plus chloramphenicol for the therapy of meningitis in a prospective, randomized multicenter cooperative trial conducted in Sweden (43) . However, cefuroxime is less active than the third-generation agents in vitro against major meningeal pathogens, especially members of the Enterobacteriaceae. Moxalactam has the following two disadvantages compared with cefotaxime and ceftriaxone for the therapy of meningitis: (i) poor in vitro activity against pneumococci and group B streptococci, supported by poor results in animal models or humans with meningitis due to these organisms (24, 25, 34; Scheld, Eur. J. Clin. Microbiol., in press); and (ii) altered platelet aggregation and bleeding disturbances at the maximal dosages necessary for the therapy of central nervous system infections (29) . The in vitro activities of ceftriaxone and cefotaxime are nearly identical (1, 14, 17, 28, 39; Scheld et al.,  in press), including the activities against the major meningeal pathogens, and both of these agents have proven efficacy in the therapy of meningitis in humans (2, 6, 8, 12, 29, 40) . The clinical experience with ceftriaxone exceeds that with cefotaxime alone for this disease. In addition, the dosing interval for ceftriaxone (every 12 to 24 h) is an advantage compared with the regimen required for cefotaxime (every 4 to 6 h). Our results demonstrate the therapeutic efficacy of once daily ceftriaxone administration in the treatment of bacterial meningitis. Similar results were observed by Martin, who treated 24 patients once daily in Zurich, Switzerland (22) . The mean CSF concentration attained 24 h after dosing in the study of Martin was 3.4 ,ug/ml, very similar to our results, and was 12-to >50-fold greater than the MBC90 of important meningeal pathogens (22) . This advantage of every 24 h compared with every 12 h dosing may prove to be minor in industrialized nations but may be extremely important in the developing countries, pending further information on relative costs. However, once daily dosing demands strict monitoring of dose administration to ensure accurate and complete dose delivery. The very critical initial dose of any antibiotic regimen for such an emergent disease as meningi-
